Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

SOPHIA ANTIPOLIS, France, Nov. 12 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that results from the first pivotal phase 3 trial for naproxcinod in patients with osteoarthritis of the knee (the 301 study) were presented on November 10, 2007 at the 71st annual meeting of the American College of Rheumatology (ACR), in Boston, Massachusetts (see NOTE). Naproxcinod is NicOx' lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide Donator (CINOD) class. The presentation contained additional efficacy data to the top-line results announced in 2006 (see press release of October 27, 2006) which showed that naproxcinod met all three co-primary endpoints of the trial. The data showed that both doses of naproxcinod (750 mg and 375 mg bid) had superior efficacy to placebo at all time points (2, 6 and 13 weeks). This presentation also contained additional safety and tolerability information, including the gastro-intestinal adverse event rates and blood pressure measurements reported for each of the treatment groups.

Detailed clinical data from the 301 study were presented, including data for each of the three co-primary efficacy endpoints: WOMAC(TM) pain subscale, WOMAC(TM) function subscale and patients' overall rating of disease status. Each of the active treatments (naproxcinod 750 mg, naproxcinod 375 mg and naproxen 500 mg bid) were statistically significantly superior to placebo (p<=0.0002) at 2, 6 and 13 weeks. In addition, standard quality of life scores showed a functional improvement for both naproxcinod doses, as well as for the naproxen group.

At week 13, both doses of naproxcinod (750 mg and 375 mg bid) showed a slight decrease in systolic blood pressure in terms of the mean change from baseline compared to placebo (0.8 and 0.2 mmHg, respectively), while a 2 mmHg increase was observed for naproxen compared to placebo. Patients' blood pressure was measured by a health care professional using
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015  Eli Lilly and Company (NYSE: LLY ... tender offer for up to $1.6 billion aggregate principal amount ... approximately $1.45 billion in aggregate principal amount of the notes ... validly withdrawn on or prior to 5:00 p.m., ... the early tender date for the offer. ...
(Date:5/27/2015)... Research and Markets ( ... the  "2015 Strategies in the UK Nucleic ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,  ... NAT laboratory practice, as well as key ... with significant market impact during the next ...
(Date:5/27/2015)... , May 27, 2015 ... has announced the addition of the  "North ... Forecasts (2014 - 2019)"  report to ... ,  , ,Mammography is a detailed type ... system to inspect breasts. A mammography exam, ...
Breaking Medicine Technology:Lilly Announces the Early Results of Its Cash Tender Offer 2Lilly Announces the Early Results of Its Cash Tender Offer 3Lilly Announces the Early Results of Its Cash Tender Offer 4Lilly Announces the Early Results of Its Cash Tender Offer 5North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2
... Oct. 13 The Care Continuum Alliance ... Award for the "Greatest Impact on Health" at ...  The ALL/PHASE protocol, which utilizes low-cost and generic medications ... successfully implemented in Kaiser Permanente communities, including those served ...
... Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna -- OOSTERHOUT, Netherlands, Oct. 13 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 4Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 5Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 6Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 7Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 8Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 9
(Date:5/28/2015)... 28, 2015 Hexagon Geospatial is pleased ... a provider of engineering, spatial data and mapping services, ... thousands of point clouds for urban change assessments in ... 2014, the BHI Spatial Data Division implemented a countywide ... aerial imagery. Collected by a variety of different digital ...
(Date:5/28/2015)... 2015 Cancer survivors who participated in ... physical activity, fitness and quality of life, according to ... Center and Jennifer Ligibel, MD, senior physician in the ... Cancer Institute. The findings will be presented at this ... Annual Meeting in Chicago. , The study, ...
(Date:5/28/2015)... May 28, 2015 The MIT Sloan ... study featuring Healthcare IQ. Members of the MIT CISR ... management team to develop the case study about Healthcare ... analytics. , The case study, ‘Healthcare IQ: Competing as ... from its beginning as a hospital financial software provider ...
(Date:5/28/2015)... Dallas urologist Mark Allen, MD ... patient education website NORTHTEXASUROLOGIST.COM developed by ... readily access current educational information on various urological ... incontinence, prostate cancer treatment, robotic surgery and female ... to educate patients on urological conditions and treatments, ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Atlanta-based Thrive ... be breaking ground this summer on an innovative new ... on resident engagement and connectivity in a unique, resort-like ... of innovative technology and southern hospitality to create a ... The 93 unit community will feature luxuriously appointed resident ...
Breaking Medicine News(10 mins):Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4Health News:Healthcare IQ, the “Switzerland” of Healthcare Spend Analytics, Featured in MIT Case Study 2Health News:Healthcare IQ, the “Switzerland” of Healthcare Spend Analytics, Featured in MIT Case Study 3Health News:Mark Allen MD, Dallas Urologist, Launches Updated Patient Education Website With a Focus on Prostate Cancer and Erectile Dysfunction Treatment 2Health News:Thrive Announces Innovative New Senior Living Community in Huntsville, AL 2
... most resistant leukemia can be treated with a superior ... fails, as showed by the clinicians at the St. ... Jude technique allows blood stem cells to come from ... aggressive, toxic treatments that usually must accompany the transplant. ...
... health benefits versus risks of an oral medicine widely prescribed ... // ,The drug — called pioglitazone — is marketed ... and Eli Lilly and Co. under the trade name Actos. ... at least 24 weeks of pioglitazone treatment in people with ...
... Chicago chemists have demonstrated for the first time how ... a few chemical reactions to predict when and where ... technique that allows them to probe blood clotting on ... a unit of measurement much narrower than the diameter ...
... in the gut has been found to be an ... to researchers at Cedars-Sinai Medical Center. ,The ... of the Annals of Internal Medicine It is ... after end of the course of treatment has ended. ...
... he would prefer not step in to fast-track a merger ... a meeting with Tony Abbott and Goulburn Murray politicians yesterday. ... and Victorian governments has still not revealed a common plan ... the border work as one. ,Mr Abbott states that ...
... cancer patient, Lisa Norris, 16 has succumbed to the accidental ... was discovered//. ,Lisa Norris, from Girvan in Ayrshire, ... She was admitted to the Beatson Oncology Centre in Glasgow, ... radiation treatments in the past 20 years. ,Following a ...
Cached Medicine News:Health News:Partial-match cell transplants for kids with resistant leukemia 2Health News:Partial-match cell transplants for kids with resistant leukemia 3Health News:Widely Prescribed Diabetes Drug Falls Short of Promise, Says New Review 2Health News:Widely Prescribed Diabetes Drug Falls Short of Promise, Says New Review 3Health News:Predicting the Dynamics of Clotting in Human Blood 2Health News:Predicting the Dynamics of Clotting in Human Blood 3Health News:IBS Sufferers Benefited by Non-Absorbable Antibiotics 2Health News:Cancer patient Dies of Massive Radiation Overdose 2
... has been designed so the surgeon can ... tissue away from the operative surface. It ... without stay-sutures or assistance. This controlled versatility ... to do other tasks, which will broaden ...
... The PowerPro® Battery System is a ... line of powered surgical instruments. The PowerPro ... software controlled battery powered instrument available on ... power system specifically designed to meet the ...
... GE OEC, the market leader ... decades of imaging experience and advanced ... with its latest entry, the MiniView ... extremity imaging has the workstation components ...
Lightweight & portable, compact station. Accurate and speedy measurement, auto-shot function, AI measuring function, focusing indicator....
Medicine Products: